Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

First Posted Date
2023-06-12
Last Posted Date
2023-06-12
Lead Sponsor
Ruijin Hospital
Target Recruit Count
332
Registration Number
NCT05899621
Locations
🇨🇳

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

First Posted Date
2023-06-08
Last Posted Date
2024-04-29
Lead Sponsor
Indiana University
Registration Number
NCT05895201
Locations
🇺🇸

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

First Posted Date
2023-06-05
Last Posted Date
2023-07-27
Lead Sponsor
Liaoning Tumor Hospital & Institute
Target Recruit Count
30
Registration Number
NCT05887726
Locations
🇨🇳

Xing Xiaojing, Shenyang, Liaoning, China

Influence of Timing PTCy in AlloSCT

First Posted Date
2023-06-02
Last Posted Date
2023-09-28
Lead Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Target Recruit Count
200
Registration Number
NCT05886335
Locations
🇪🇸

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL

First Posted Date
2023-06-01
Last Posted Date
2024-11-13
Lead Sponsor
Affimed GmbH
Target Recruit Count
154
Registration Number
NCT05883449
Locations
🇺🇸

UNC Immunotherapy Team, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

🇺🇸

O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States

🇺🇸

City of Hope National Medical Center, Duarte, California, United States

and more 12 locations

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

First Posted Date
2023-06-01
Last Posted Date
2023-06-27
Lead Sponsor
Fudan University
Target Recruit Count
1406
Registration Number
NCT05883852
Locations
🇨🇳

Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

First Posted Date
2023-05-31
Last Posted Date
2024-04-12
Lead Sponsor
TCRCure Biopharma Ltd.
Target Recruit Count
18
Registration Number
NCT05881525
Locations
🇨🇳

TCRCure Biopharma Ltd., Chongqing, China

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

First Posted Date
2023-05-24
Last Posted Date
2023-05-25
Lead Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Target Recruit Count
82
Registration Number
NCT05872412
Locations
🇧🇩

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

First Posted Date
2023-05-24
Last Posted Date
2024-03-15
Lead Sponsor
Adam Kittai
Target Recruit Count
24
Registration Number
NCT05873712
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases

First Posted Date
2023-05-23
Last Posted Date
2024-12-19
Lead Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Target Recruit Count
129
Registration Number
NCT05869955
Locations
🇪🇸

Hospital Universitario Reina Sofia, Cordoba, Spain

🇺🇸

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 51 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy